Raymond James Maintains Outperform on Leap Therapeutics, Lowers Price Target to $17
Portfolio Pulse from richadhand@benzinga.com
Raymond James analyst Steven Seedhouse maintains an Outperform rating on Leap Therapeutics (NASDAQ:LPTX) but lowers the price target from $20 to $17.
June 23, 2023 | 11:45 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Raymond James maintains Outperform rating on Leap Therapeutics (LPTX) but lowers the price target from $20 to $17.
The news of Raymond James maintaining an Outperform rating on Leap Therapeutics is positive for the stock. However, the lowering of the price target from $20 to $17 may create some uncertainty among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100